With 1.79 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.98 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $900.0 whereas the lowest price it dropped to was $888.28. The 52-week range on LLY shows that it touched its highest point at $972.53 and its lowest point at $547.61 during that stretch. It currently has a 1-year price target of $1020.55. With its current market cap of 847.14 billion, LLY has annualized dividend of $5.03 while the current yield stands at 0.56%. Beta for the stock currently stands at 0.42.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LLY was down-trending over the past week, with a drop of -2.81%, but this was down by -3.60% over a month. Three-month performance surged to 10.78% while six-month performance rose 22.96%. The stock gained 50.45% in the past year, while it has gained 52.91% so far this year. A look at the trailing 12-month EPS for LLY yields 8.01 with Next year EPS estimates of 22.72. For the next quarter, that number is 1.45. This implies an EPS growth rate of 111.59% for this year and 69.89% for next year. EPS is expected to grow by 34.55% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 13.74%.
Float and Shares Shorts:
At present, 949.38 million LLY shares are outstanding with a float of 851.72 million shares on hand for trading. On 2024-09-30, short shares totaled 5.79 million, which was 64.0 higher than short shares on 1724976000. In addition to Mr. David A. Ricks as the firm’s Chairman, CEO & President, Dr. Daniel M. Skovronsky M.D., Ph.D. serves as its EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology.
Institutional Ownership:
Through their ownership of 0.83591 of LLY’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, LLY reported revenue of $11302800000.0 and operating income of $4418500000.0. The EBITDA in the recently reported quarter was $4862400000.0 and diluted EPS was $3.28.
